查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
北美癫痫市场预测至 2030 年 - 区域分析 - 按类型、给药途径、治疗类型、年龄层和配销通路
市场调查报告书
商品编码
1592586

北美癫痫市场预测至 2030 年 - 区域分析 - 按类型、给药途径、治疗类型、年龄层和配销通路

North America Epilepsy Market Forecast to 2030 - Regional Analysis - by Type, Route of Administration, Treatment Type, Age Group, and Distribution Channel
出版日期: | 出版商: The Insight Partners | 英文 135 Pages | 订单完成后即时交付

价格

2022年北美癫痫市场价值为25.771亿美元，预计到2030年将达到36.0934亿美元；预计2022年至2030年复合年增长率为4.3%。

癫痫盛行率上升推动北美癫痫市场

癫痫，也称为癫痫症，是一种慢性脑部疾病。它的特征是反覆发作，是身体一部分或整个身体不自主运动的短暂发作。癫痫发作会改变感觉、行为、意识和肌肉运动。癫痫可能是由于遗传性疾病或后天性脑损伤（例如外伤或中风）引起的。根据世界卫生组织 (WHO) 2023 年 2 月发布的资料，癫痫在全球疾病负担中占有很大份额，影响全球近 5,000 万人。此外，估计每 1,000 人中有 4-10 人患有活动性癫痫（即需要治疗或持续癫痫发作）。每年有近 500 万人被诊断出患有癫痫症。据估计，高收入国家每年每 10 万人中有 49 人患有癫痫。在低收入和中等收入国家，这一数字可高达每 10 万人 139 人。癫痫发生率激增可归因于道路交通伤害和出生相关伤害的增加，以及神经囊虫病或疟疾等地方性疾病的风险增加。世界卫生组织也指出，大约 70% 的癫痫患者可以透过药物治疗消除癫痫发作。控制癫痫的治疗方法包括抗癫痫药物、特殊饮食（除抗癫痫药物）和手术；然而，抗癫痫药物治疗是大多数患者的主要治疗方法。因此，全球癫痫盛行率的上升推动了市场的成长。

北美癫痫市场概况

北美癫痫市场分为美国、加拿大和墨西哥。该地区的市场成长归因于癫痫患者数量的增加、人口老化、该地区癫痫药物领域的持续研发、新产品的监管批准增加以及事故和事故数量的增加。

北美癫痫市场收入及 2030 年预测（百万美元）

北美癫痫市场细分

北美癫痫市场按类型、给药途径、治疗类型、年龄层、配销通路和国家分类。

依类型，北美癫痫市场分为进行性肌阵挛癫痫、反射性癫痫、全身性癫痫等。 2022 年，全身性癫痫细分市场占最大市场。

就给药途径而言，北美癫痫市场分为口服、肠胃外和其他。 2022 年，口腔细分市场占据最大的市场份额。

依治疗类型，北美癫痫市场分为第一代药物、第二代药物和第三代药物。 2022年，第三代药物细分市场占据最大市场份额。

根据年龄组，北美癫痫市场分为成人和儿童。 2022 年，成人市场占有更大的市场份额。

从配销通路来看，北美癫痫市场分为医院药局、零售药局等。 2022 年，医院药局领域占据最大的市场份额。

依国家划分，北美癫痫市场分为美国、加拿大和墨西哥。 2022 年，美国在北美癫痫市场份额中占据主导地位。

雅培实验室、辉瑞公司、卫材有限公司、UCB SA、LivaNova Plc、诺华公司、美敦力公司、葛兰素史克公司和 H. Lundbeck AS 是北美癫痫市场上的一些领导公司。

目录

第 1 章：简介

第 2 章：执行摘要

  • 主要见解
  • 市场吸引力

第 3 章：研究方法

  • 覆盖范围
  • 二次研究
  • 初步研究

第 4 章：北美癫痫治疗方法的管道研究

  • 癫痫治疗方法的管道研究
    • 细胞和基因治疗方法
    • 胶囊细胞生物递送（ECB）系统
    • 癫痫基因治疗临床概述
      • 癫痫临床研究采用基因疗法
      • 癫痫病毒载体的管道研究
      • 癫痫非病毒载体的管道研究
      • 腺相关病毒 (AAV) 介导的神经调节胜肽 - 概述
      • 基因治疗方法的神经营养因子
      • 人类癫痫表型的钾通道
      • 酶诱导抗癫痫药

第 5 章：北美癫痫市场 - 主要市场动态

  • 市场驱动因素
    • 癫痫盛行率上升
    • 增加癫痫疗法开发的投资
  • 市场限制
    • 产品召回
  • 市场机会
    • 组织所进行的意识计画激增
  • 未来趋势
    • 基因疗法作为有前景的治疗方法
  • 驱动因素和限制的影响：

第 6 章：癫痫市场 - 北美分析

  • 北美：癫痫市场概述

第 7 章：北美癫痫市场分析 - 按类型

  • 概述
  • 进行性肌阵挛癫痫
  • 反射性癫痫
  • 全身性癫痫
  • 其他

第 8 章：北美癫痫市场分析 - 按给药途径

  • 概述
  • 口服
  • 注射用
  • 其他的

第 9 章：北美癫痫市场分析 - 按治疗类型

  • 概述
  • 第一代药物
  • 第二代药物
  • 第三代药物

第 10 章：北美癫痫市场分析 - 按年龄组

  • 概述
  • 成人
  • 孩子们

第 11 章：北美癫痫市场分析 - 按配销通路

  • 概述
  • 医院药房
  • 零售药局
  • 其他的

第 12 章：北美癫痫市场 - 国家分析

    • 北美洲
      • 墨西哥

第 13 章：产业格局

  • 概述
  • 癫痫市场的成长策略
  • 有机成长策略
    • 概述
  • 无机成长策略
    • 概述

第 14 章：公司简介

  • Abbott Laboratories
  • Pfizer Inc
  • Eisai Co Ltd
  • UCB SA
  • LivaNova Plc
  • Novartis AG
  • Medtronic Plc
  • GSK Plc
  • H. Lundbeck AS

第 15 章：附录

Product Code: BMIRE00030781

The North America epilepsy market was valued at US$ 2,577.10 million in 2022 and is expected to reach US$ 3,609.34 million by 2030; it is estimated to register a CAGR of 4.3% from 2022 to 2030.

Rising Prevalence of Epilepsy Fuels North America Epilepsy Market

Epilepsy, also termed a seizure disorder, is a chronic disease of the brain. It is characterized by recurrent seizures, which are brief episodes of involuntary movement of a part of the body or the entire body. Seizures can alter sensations, behaviors, awareness, and muscle movements. Epilepsy may occur due to a genetic disorder or an acquired brain injury, such as a trauma or stroke. According to data published by the World Health Organization (WHO) in February 2023, epilepsy accounts for a significant share of the worldwide disease burden, affecting nearly 50 million people across the world. Moreover, 4-10 persons per 1,000 individuals are estimated to have active epilepsy (i.e., with the need for treatment or continuing seizures). Nearly 5 million people are diagnosed with epilepsy every year. High-income countries are estimated to report epilepsy at a rate of 49 per 100,000 people annually. This number can reach as high as 139 per 100,000 individuals in low- and middle-income countries. An upsurge in epilepsy incidence can be attributed to the higher count of road traffic injuries and birth-related injuries, and the elevated risk of endemic conditions such as neurocysticercosis or malaria. The WHO also states that approximately 70% of individuals with epilepsy can become seizure-free with the use of medications. Treatments to control epilepsy include anti-epileptic medications, special diets (in addition to anti-seizure medications), and surgery; however, anti-epileptic drug therapy is the primary treatment prescribed for most patients. Thus, the rising prevalence of epilepsy worldwide drives market growth.

North America Epilepsy Market Overview

The North America epilepsy market is segmented into the US, Canada, and Mexico. The market growth in this region is attributed due to the rise in number of people affected with epilepsy, growing aging population, ongoing R&D in the field of epilepsy drugs in the region, growing regulatory approvals for new product, and rise in number of accidents and brain injuries in epilepsy drugs.

North America Epilepsy Market Revenue and Forecast to 2030 (US$ Million)

North America Epilepsy Market Segmentation

The North America epilepsy market is categorized into type, route of administration, treatment type, age group, distribution channel, and country.

Based on type, the North America epilepsy market is categorized into progressive myoclonic epilepsy, reflex epilepsy, generalized epilepsy, and other. The generalized epilepsy segment held the largest market share in 2022.

In terms of route of administration, the North America epilepsy market is categorized into oral, parenteral, and others. The oral segment held the largest market share in 2022.

By treatment type, the North America epilepsy market is segmented into first generation drugs, second generation drugs, and third generation drugs. The third generation drugs segment held the largest market share in 2022.

Based on age group, the North America epilepsy market is bifurcated into adult and children. The adult segment held a larger market share in 2022.

In terms of distribution channel, the North America epilepsy market is categorized into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held the largest market share in 2022.

By country, the North America epilepsy market is segmented into the US, Canada, and Mexico. The US dominated the North America epilepsy market share in 2022.

Abbott Laboratories, Pfizer Inc, Eisai Co Ltd, UCB SA, LivaNova Plc, Novartis AG, Medtronic Plc, GSK Plc, and H. Lundbeck AS are some of the leading companies operating in the North America epilepsy market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. North America Pipeline Studies for Epilepsy Therapy Approaches

  • 4.1 Pipeline Studies for Epilepsy Therapy Approaches
    • 4.1.1 Cell and Gene Therapy Approaches
    • 4.1.2 Encapsulated cell bio delivery (ECB) system
    • 4.1.3 Gene Therapy for Epilepsy Clinical Overview
      • 4.1.3.1 Genetic Therapies Adopted for Clinic Research of Epilepsy
        • 4.1.3.1.1 Gene Supplementation - Overview
        • 4.1.3.1.2 Gene Modulation - Overview
        • 4.1.3.1.3 Antisense Oligonucleotides and RNA Interference - Overview
        • 4.1.3.1.4 Neuropeptides - Overview
        • 4.1.3.1.5 Engineered Channels - Overview
        • 4.1.3.1.6 Endogenous Channels - Overview
      • 4.1.3.2 Pipeline Studies of Viral Vectors for Epilepsy
      • 4.1.3.3 Pipeline Studies of Non-Viral Vectors for Epilepsy
        • 4.1.3.3.1 Polymer-based Non-Viral Vectors for Epilepsy
        • 4.1.3.3.2 Lipid-based Non-Viral Vectors for Epilepsy
      • 4.1.3.4 Adeno-Associated Virus (AAV)-Mediated Neuromodulatory Peptides - Overview
      • 4.1.3.5 Neurotrophic Factors for Gene Therapy Approaches
      • 4.1.3.6 Potassium Channels for Human Epileptic Phenotypes
      • 4.1.3.7 Enzyme Inducing Antiepileptic Drugs

5. North America Epilepsy Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Rising Prevalence of Epilepsy
    • 5.1.2 Increasing Investments in Development of Epilepsy Therapies
  • 5.2 Market Restraints
    • 5.2.1 Recall of Products
  • 5.3 Market Opportunities
    • 5.3.1 Surge in Awareness Programs Conducted by Organizations
  • 5.4 Future Trends
    • 5.4.1 Gene Therapy as Promising Treatment Approach
  • 5.5 Impact of Drivers and Restraints:

6. Epilepsy Market - North America Analysis

  • 6.1 North America: Epilepsy Market Overview

7. North America Epilepsy Market Analysis - by Type

  • 7.1 Overview
  • 7.2 Progressive Myoclonic Epilepsy
    • 7.2.1 Overview
    • 7.2.2 Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.3 Reflex Epilepsy
    • 7.3.1 Overview
    • 7.3.2 Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Generalized Epilepsy
    • 7.4.1 Overview
    • 7.4.2 Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 Other
    • 7.5.1 Overview
    • 7.5.2 Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Epilepsy Market Analysis - by Route of Administration

  • 8.1 Overview
  • 8.2 Oral
    • 8.2.1 Overview
    • 8.2.2 Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.3 Parenteral
    • 8.3.1 Overview
    • 8.3.2 Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Others
    • 8.4.1 Overview
    • 8.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

9. North America Epilepsy Market Analysis - by Treatment Type

  • 9.1 Overview
  • 9.2 First Generation Drugs
    • 9.2.1 Overview
    • 9.2.2 First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.3 Second Generation Drugs
    • 9.3.1 Overview
    • 9.3.2 Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.4 Third Generation Drugs
    • 9.4.1 Overview
    • 9.4.2 Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

10. North America Epilepsy Market Analysis - by Age Group

  • 10.1 Overview
  • 10.2 Adult
    • 10.2.1 Overview
    • 10.2.2 Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.3 Children
    • 10.3.1 Overview
    • 10.3.2 Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

11. North America Epilepsy Market Analysis - by Distribution Channel

  • 11.1 Overview
  • 11.2 Hospital Pharmacies
    • 11.2.1 Overview
    • 11.2.2 Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 11.3 Retail Pharmacies
    • 11.3.1 Overview
    • 11.3.2 Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 11.4 Others
    • 11.4.1 Overview
    • 11.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

12. North America Epilepsy Market - Country Analysis

  • 12.1 North America Epilepsy Market Overview
    • 12.1.1 North America: Epilepsy Market Breakdown- by Country, 2022 and 2030 (%)
        • 12.1.1.1.1 United States: Epilepsy Market Overview
        • 12.1.1.1.2 United States: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
        • 12.1.1.1.3 United States: Epilepsy Market Breakdown, by Type
        • 12.1.1.1.4 United States: Epilepsy Market Breakdown, by Route of Administration
        • 12.1.1.1.5 United States: Epilepsy Market Breakdown, by Treatment Type
        • 12.1.1.1.6 United States: Epilepsy Market Breakdown, by Age Group
        • 12.1.1.1.7 United States: Epilepsy Market Breakdown, by Distribution Channel
        • 12.1.1.1.8 Canada: Epilepsy Market Overview
        • 12.1.1.1.9 Canada: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
        • 12.1.1.1.10 Canada: Epilepsy Market Breakdown, by Type
        • 12.1.1.1.11 Canada: Epilepsy Market Breakdown, by Route of Administration
        • 12.1.1.1.12 Canada: Epilepsy Market Breakdown, by Treatment Type
        • 12.1.1.1.13 Canada: Epilepsy Market Breakdown, by Age Group
        • 12.1.1.1.14 Canada: Epilepsy Market Breakdown, by Distribution Channel
        • 12.1.1.1.15 Mexico: Epilepsy Market Overview
      • 12.1.1.2 Mexico: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
        • 12.1.1.2.1 Mexico: Epilepsy Market Breakdown, by Type
        • 12.1.1.2.2 Mexico: Epilepsy Market Breakdown, by Route of Administration
        • 12.1.1.2.3 Mexico: Epilepsy Market Breakdown, by Treatment Type
        • 12.1.1.2.4 Mexico: Epilepsy Market Breakdown, by Age Group
        • 12.1.1.2.5 Mexico: Epilepsy Market Breakdown, by Distribution Channel

13. Industry Landscape

  • 13.1 Overview
  • 13.2 Growth Strategies in Epilepsy Market
  • 13.3 Organic Growth Strategies
    • 13.3.1 Overview
  • 13.4 Inorganic Growth Strategies
    • 13.4.1 Overview

14. Company Profiles

  • 14.1 Abbott Laboratories
    • 14.1.1 Key Facts
    • 14.1.2 Business Description
    • 14.1.3 Products and Services
    • 14.1.4 Financial Overview
    • 14.1.5 SWOT Analysis
    • 14.1.6 Key Developments
  • 14.2 Pfizer Inc
    • 14.2.1 Key Facts
    • 14.2.2 Business Description
    • 14.2.3 Products and Services
    • 14.2.4 Financial Overview
    • 14.2.5 SWOT Analysis
    • 14.2.6 Key Developments
  • 14.3 Eisai Co Ltd
    • 14.3.1 Key Facts
    • 14.3.2 Business Description
    • 14.3.3 Products and Services
    • 14.3.4 Financial Overview
    • 14.3.5 SWOT Analysis
    • 14.3.6 Key Developments
  • 14.4 UCB SA
    • 14.4.1 Key Facts
    • 14.4.2 Business Description
    • 14.4.3 Products and Services
    • 14.4.4 Financial Overview
    • 14.4.5 SWOT Analysis
    • 14.4.6 Key Developments
  • 14.5 LivaNova Plc
    • 14.5.1 Key Facts
    • 14.5.2 Business Description
    • 14.5.3 Products and Services
    • 14.5.4 Financial Overview
    • 14.5.5 SWOT Analysis
    • 14.5.6 Key Developments
  • 14.6 Novartis AG
    • 14.6.1 Key Facts
    • 14.6.2 Business Description
    • 14.6.3 Products and Services
    • 14.6.4 Financial Overview
    • 14.6.5 SWOT Analysis
    • 14.6.6 Key Developments
  • 14.7 Medtronic Plc
    • 14.7.1 Key Facts
    • 14.7.2 Business Description
    • 14.7.3 Products and Services
    • 14.7.4 Financial Overview
    • 14.7.5 SWOT Analysis
    • 14.7.6 Key Developments
  • 14.8 GSK Plc
    • 14.8.1 Key Facts
    • 14.8.2 Business Description
    • 14.8.3 Products and Services
    • 14.8.4 Financial Overview
    • 14.8.5 SWOT Analysis
    • 14.8.6 Key Developments
  • 14.9 H. Lundbeck AS
    • 14.9.1 Key Facts
    • 14.9.2 Business Description
    • 14.9.3 Products and Services
    • 14.9.4 Financial Overview
    • 14.9.5 SWOT Analysis
    • 14.9.6 Key Developments

15. Appendix

  • 15.1 About The Insight Partners

List Of Tables

  • Table 1. North America Epilepsy Market Segmentation
  • Table 2. Cell Therapy Approach - An Overview
  • Table 3. Gene Therapy Approach - An Overview
  • Table 4. Encapsulated cell bio delivery (ECB) system Cell and Gene Therapy Approach - An Overview
  • Table 5. Preclinically Tested Genetic Therapies for Epilepsy
  • Table 6. Clinical Trials for Epilepsy Gene Therapy: Overview
  • Table 7. Viral Vectors Comparison with respect to Various Parameters
  • Table 8. Subfamilies of Human K+ Channels Involved in Epilepsies
  • Table 9. Enzyme-Inducing Antiepileptic Drugs
  • Table 10. Enzyme-Inducing Antiepileptic Drugs & Drug Target Types Overview
  • Table 11. United States: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Type
  • Table 12. United States: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
  • Table 13. United States: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Treatment Type
  • Table 14. United States: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Age Group
  • Table 15. United States: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
  • Table 16. Canada: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Type
  • Table 17. Canada: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
  • Table 18. Canada: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Treatment Type
  • Table 19. Canada: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Age Group
  • Table 20. Canada: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
  • Table 21. Mexico: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Type
  • Table 22. Mexico: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
  • Table 23. Mexico: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Treatment Type
  • Table 24. Mexico: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Age Group
  • Table 25. Mexico: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
  • Table 26. Recent Organic Growth Strategies in Epilepsy Market
  • Table 27. Recent Inorganic Growth Strategies in the Epilepsy Market

List Of Figures

  • Figure 1. North America Epilepsy Market Segmentation, by Country
  • Figure 2. Epilepsy Market - Key Market Dynamics
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Epilepsy Market Revenue (US$ Million), 2020-2030
  • Figure 5. Epilepsy Market Share (%) - by Type (2022 and 2030)
  • Figure 6. Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 7. Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 10. Epilepsy Market Share (%) - by Route of Administration (2022 and 2030)
  • Figure 11. Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. Epilepsy Market Share (%) - by Treatment Type (2022 and 2030)
  • Figure 15. First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 17. Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. Epilepsy Market Share (%) - by Age Group (2022 and 2030)
  • Figure 19. Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 20. Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 21. Epilepsy Market Share (%) - by Distribution Channel (2022 and 2030)
  • Figure 22. Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 23. Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 24. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 25. North America: Epilepsy Market, by Key Country - Revenue (2022) (US$ Million)
  • Figure 26. North America: Epilepsy Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 27. United States: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 28. Canada: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 29. Mexico: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 30. Growth Strategies in Epilepsy Market